260 related articles for article (PubMed ID: 10591540)
21. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
22. Debrisoquine hydroxylase (CYP2D6) and prostate cancer.
Febbo PG; Kantoff PW; Giovannucci E; Brown M; Chang G; Hennekens CH; Stampfer M
Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1075-8. PubMed ID: 9865424
[TBL] [Abstract][Full Text] [Related]
23. Characterization of cytochrome P450 2D6 alleles using the Invader system.
Nevilie M; Selzer R; Aizenstein B; Maguire M; Hogan K; Walton R; Welsh K; Neri B; de Arruda M
Biotechniques; 2002 Jun; Suppl():34-8, 40-3. PubMed ID: 12083395
[TBL] [Abstract][Full Text] [Related]
24. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
[TBL] [Abstract][Full Text] [Related]
25. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
26. Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan).
Kouhi H; Hamzeiy H; Barar J; Asadi M; Omidi Y
Genet Test Mol Biomarkers; 2009 Oct; 13(5):665-70. PubMed ID: 19715474
[TBL] [Abstract][Full Text] [Related]
27. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy.
Planté-Bordeneuve V; Bandmann O; Wenning G; Quinn NP; Daniel SE; Harding AE
Mov Disord; 1995 May; 10(3):277-8. PubMed ID: 7651442
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of CYP2D6 in Chinese mainland.
Ji L; Pan S; Wu J; Marti-Jaun J; Hersberger M
Chin Med J (Engl); 2002 Dec; 115(12):1780-4. PubMed ID: 12622923
[TBL] [Abstract][Full Text] [Related]
29. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease.
Deng Y; Newman B; Dunne MP; Silburn PA; Mellick GD
Ann Neurol; 2004 Jun; 55(6):897. PubMed ID: 15174030
[No Abstract] [Full Text] [Related]
30. Genetic polymorphism of CYP2D6 in patients with cardiovascular disease -- a cohort study.
Teh LK; Zilfalil BA; Marina I; Rosemi BS; Ismail R
J Clin Pharm Ther; 2004 Dec; 29(6):559-64. PubMed ID: 15584944
[TBL] [Abstract][Full Text] [Related]
31. [Correlation of genetic polymorphism of cytochrome P4502D6 with dextromethorphan oxidative metabolism in Chinese].
Cai W; Chen B; Tao X; Ling S; Zhang Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Jun; 17(3):181-4. PubMed ID: 10837520
[TBL] [Abstract][Full Text] [Related]
32. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease.
Elbaz A; Levecque C; Clavel J; Vidal JS; Richard F; Amouyel P; Alpérovitch A; Chartier-Harlin MC; Tzourio C
Ann Neurol; 2004 Mar; 55(3):430-4. PubMed ID: 14991823
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 genetic polymorphism in South Indian populations.
Naveen AT; Adithan C; Soya SS; Gerard N; Krishnamoorthy R
Biol Pharm Bull; 2006 Aug; 29(8):1655-8. PubMed ID: 16880622
[TBL] [Abstract][Full Text] [Related]
34. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10.
Nishida Y; Fukuda T; Yamamoto I; Azuma J
Pharmacogenetics; 2000 Aug; 10(6):567-70. PubMed ID: 10975611
[No Abstract] [Full Text] [Related]
35. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Toscano C; Raimundo S; Klein K; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):767-70. PubMed ID: 17001296
[TBL] [Abstract][Full Text] [Related]
36. [Genetic polymorphism of CYP-1A1, CYP2D6 and risks of chronic benzene poisoning].
Gu SY; Zhang ZB; Cao DZ; Wan JX; Gao XL; Jin XP; Xia ZL
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2006 May; 24(5):266-9. PubMed ID: 16737584
[TBL] [Abstract][Full Text] [Related]
37. CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C.
Hijikata M; Miyakawa H; Matsushita M; Kako M; Ohta Y; Mishiro S
Biochem Biophys Res Commun; 2000 Apr; 270(3):922-6. PubMed ID: 10772926
[TBL] [Abstract][Full Text] [Related]
38. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Schaeffeler E; Schwab M; Eichelbaum M; Zanger UM
Hum Mutat; 2003 Dec; 22(6):476-85. PubMed ID: 14635107
[TBL] [Abstract][Full Text] [Related]
39. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.
Gaedigk A; Gotschall RR; Forbes NS; Simon SD; Kearns GL; Leeder JS
Pharmacogenetics; 1999 Dec; 9(6):669-82. PubMed ID: 10634130
[TBL] [Abstract][Full Text] [Related]
40. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
Christensen PM; Gøtzsche PC; Brøsen K
Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
